Kynurenine is correlated with IL-1β in plasma of schizophrenia patients
- 225 Downloads
The etiology of schizophrenia is still unclear. It is well-known that pro-inflammatory cytokines are higher in schizophrenia patients since the first episode psychosis comparing to healthy controls. Inflammatory downstream cascades influence different cellular pathways, like the displacement of the tryptophan (TRP) metabolism to the production of kynurenine (KYN) instead of serotonin, which results in the generation of several neuro and immunoactive metabolites. The aim of this study was to determine TRP, KYN and IL-1β plasma levels in first-onset schizophrenia (n = 28) and healthy controls (n = 30). The plasmatic levels of TRP and KYN were decreased in schizophrenic patients (p = 0.004 and p = 0.002, respectively), but there was no difference in the ratio of KYN/TRP (p = 0.554) or either in IL-1β (p = 0.101). Positive correlation was observed between KYN and IL-1β only in the schizophrenia group (r = 0.461, p = 0.021). And, there was also positive correlation between KYN and Positive and Negative Symptoms Scale (PANSS) (r = 0.395, p = 0.037). There is no correlation between the other analytes and other parameters of PANSS. Although our results of KYN have been different than expected and there was no difference in the KYN/TRP ratio, we observed a positive correlation between IL-1β and KYN, corroborating findings that pro-inflammatory agents hold up the KYN pathway.
KeywordsKynurenine IL-1β Tryptophan Schizophrenia
The present work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP Grants Nos. 2013/10350-9 and 2014/20913-3); Instituto Nacional de Biomarcadores em Neuropsiquiatria (Grant No. 2014/50873-3). The Laboratory of Neuroscience receives financial support from Associação Beneficente Alzira Denise Hertzog da Silva (ABADHS) and JNK Empreendimentos e Incorporações.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capo M, Corigliano V, Scaccionoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Grandini R, Nistico R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F, Simmaco M (2015) Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 5:17799CrossRefPubMedPubMedCentralGoogle Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders. Research version. Non-patient edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, New YorkGoogle Scholar
- Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M (2006) The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139:655–662CrossRefPubMedGoogle Scholar
- Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Ursonomiya M, Nakatani M, Sadamoto K, Yoshio T (2014) Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One 9:101652CrossRefGoogle Scholar
- Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473CrossRefPubMedGoogle Scholar
- Kegel ME, Svensson CI, Erhardt S (2011) IL-1 induces IDO and TDO transcription and provokes the release of kynurenic acid from human astrocytes in vitro. Progr No 24019/E7 Neurosci Meet Planner Washington, DC. Soc Neurosci OnlineGoogle Scholar
- Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25:1576–1581CrossRefPubMedGoogle Scholar
- Okusaga O, Fuchs D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Cook TB, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT (2016) Kynurenine and tryptophan levels in patients with schizophrenia and elevated antigliadin immunoglobulin G antibodies. Psychosom Med 78:931–939CrossRefPubMedPubMedCentralGoogle Scholar
- Raison CL, Miller AH (2004) Brain–immune system interaction: relevance to the pathophysiology and treatment of neuropsychiatric disorders. In: Schatzberg AF, Nemeroff CB (eds) The American psychiatric publishing textbook of psychopharmacology, 3rd edn. American Psychiatric Press, Washington, pp 147–162Google Scholar
- Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G (2015) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133PubMedPubMedCentralGoogle Scholar
- Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, Vawter MP, Backlund L, Sullivan PF, Sklar P, Smoller JW, Magnusson PK, Hultman CM, Walther-Jallow L, Svensson CI, Lichtenstein P, Schalling M, Engberg G, Erhardt S, Landén M (2016) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry 21:1342–1350CrossRefPubMedGoogle Scholar